Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06832839
Recruiting Observational

Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease

NCT06832839 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Observational
Started
2024-12-16
Last updated
2025-02-18

Condition(s) studied

Moyamoya Disease

Investigational drug(s) / intervention(s)

Revascularization

Revascularization: Revascularization

Study summary

The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease. * Please sign the informed consent form. * Participants must be between 18 and 60 years of age. Exclusion Criteria: * Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome. * Individuals younger than 18 years or older than 60 years. * Those with contraindications for magnetic resonance imaging. * Patients who are unable to complete cognitive brain assessments

Primary outcome measure(s)

  • Change in composite score of neurocognitive function at 6 months after treatment. — 6 months during follow-up
    The composite score of neurocognitive function, including Weschsler Adult Intelligence Scale-4th Edition (WAIS-IV), MATRICS Consensus Cognitive Battery (MCCB), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Rey-Osterrieth complex figure (ROCF), Trail Making Test (TMT), Stroop test, Verbal Fluency Test (VFT), and Boston Naming Test (BNT) will be collected before and 6 months after treatment.

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing China Recruiting

More Beijing Tiantan Hospital trials in China

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma Active, not recruiting
Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) Recruiting
Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY) Recruiting
Risk Prediction Model for Cerebrovascular Events in Carotid Artery Stenosis Enrolling by invitation
The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia Recruiting

Other trials for the same condition

Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease. Enrolling by invitation
Treatment of Moyamoya Disease With iPSC-derived Exosomes Recruiting
Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial Starting soon
5T MRI and Metabolomics-Based Hemorrhage Risk Prediction in Moyamoya Disease Recruiting
The Evolution and Prognosis of Moyamoya Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06832839 on ClinicalTrials.gov ↗ ← All trials in China